2025 年 3 月 2 日 公司研究 关联方境外债重组落地，基础物管稳健增长 事件：关联方境外债重组计划获得超过 95%的债权人投票赞成。 2 月 24 日，世茂服务关联方世茂集团发布公告，其境外债重组计划已获得 2053 名（占出席人数的 98.75%）持有投票计划债权总额约 110 亿美元（占债权总额 的 95.39%）的计划债权人投票赞成，后续世茂集团将寻求高等法院对重组计划 进行批准和裁决。 点评：关联方境外债重组落地，基础物管稳健增长，地产关联业务影响较小。 1) 基础物管稳健增长，增值业务有所调整。2024H1 公司实现营业收入 40.3 亿 元，同比下降 1.6%，毛利 8.1 亿元，同比下降 5.9%，归母净利润 1.8 亿元，同 比增长 18.9%。期内，物业管理/社区增值/非业主增值/城市服务分别实现收入 27.6/5.9/0.8/6.0 亿元，同比分别为+5.7%/-17.3%/-33.2%/-7.9%，基础物管业 务实现稳健增长，社区增值和非业主增值不同程度受到房地产市场和国内经济形 势及消费环境影响，业务开展面临一定挑战；城市服务收入下滑则由于公司主动 退出了部分利润率较低及信用期 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 47.25, representing a potential upside of 48.11% from the current stock price of HKD 31.90 [1]. Core Insights - The company's Q4 2024 performance met expectations, with a year-to-date low double-digit growth forecast. The net revenue for Q4 was HKD 11.29 billion, recovering to 87.1% of the 2019 level, with a year-on-year increase of 9.4% and a quarter-on-quarter increase of 5.9% [2][3]. - The introduction of smart gaming tables and the launch of new products, particularly the Capella Hotel and Resort, are expected to enhance market share. The company has a strong balance sheet with net cash of HKD 27.1 billion, the strongest in the industry [2][3]. Financial Summary - Total net revenue is projected to grow from HKD 35.68 billion in 2023 to HKD 55.18 billion by 2027, reflecting a compound annual growth rate (CAGR) of 10.3% [2][3]. - EBITDA is expected to increase from HKD 9.96 billion in 2023 to HKD 16.89 billion in 2027, with an EBITDA margin improving from 27.9% to 30.6% over the same period [2][3]. - Net profit is forecasted to rise from HKD 6.83 billion in 2023 to HKD 12.62 billion in 2027, with a net profit margin increasing from 19.1% to 22.9% [2][3]. Operational Highlights - The company reported a strong performance in its flagship properties, with net revenues for Galaxy Macau and StarWorld Hotel increasing by 12% and 3% year-on-year, respectively [2]. - The occupancy rates for Galaxy Macau and StarWorld Hotel were reported at 98% and 100%, respectively, indicating robust demand [2]. - The company is advancing its development projects, including the introduction of the Capella Hotel and Resort in mid-2025 and the ongoing construction of the fourth phase of Galaxy Macau, expected to be completed by 2027 [2][3].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [3][81]. Core Insights - The company, MAOGEPING, is a leading high-end beauty group in China, being the only domestic company among the top ten high-end beauty groups in the market [2][12]. - The company has demonstrated rapid growth, with a net profit CAGR of 41.4% from 2021 to 2023, outpacing revenue growth, and maintaining a steady increase in net profit margin [2][19]. - The flagship brand MAOGEPING, launched in 2000, is the first high-end beauty brand in China and ranks as the twelfth largest high-end beauty brand by retail sales in 2023 [2][12]. Summary by Sections Company Overview - MAOGEPING has been deeply engaged in the beauty industry for 25 years and has established itself as a leading high-end beauty group in China [2][12]. - The company operates two main brands: MAOGEPING and Zhi Ai Zhong Sheng, targeting different market segments [17][18]. Business Operations - The company has 372 self-operated counters across China, ranking second among domestic beauty brands, and has a strong online presence with significant revenue and repurchase rates exceeding industry averages [3][19]. - The product portfolio includes a diverse range of cosmetics, skincare, and newly developed perfumes, with a focus on innovation and consumer demand [3][67]. Financial Performance - The company’s revenue grew from 15.8 billion yuan in 2021 to 28.9 billion yuan in 2023, with a CAGR of 35.3% [19]. - The projected revenues for 2024, 2025, and 2026 are 39.1 billion yuan, 51.1 billion yuan, and 65.1 billion yuan, respectively, with corresponding year-on-year growth rates of 35.6%, 30.7%, and 27.2% [81][82]. Market Potential - The Chinese beauty market is expanding, with the color cosmetics market size reaching 116.8 billion yuan in 2023, and significant growth potential remains compared to per capita spending in countries like Japan and South Korea [30][31]. - The high-end beauty market in China is projected to grow from 1,942 billion yuan in 2023 to 3,110 billion yuan by 2028, indicating a robust growth trajectory [43][44]. Future Growth Drivers - The brand leverages the IP of its founder, MAO Ge Ping, enhancing brand differentiation and consumer appeal through a unique blend of light and shadow aesthetics with Eastern cultural elements [51][53]. - The company is expanding its product lines, including a new perfume series launched in January 2025, to capture additional market segments [74][75].

中国能源 威廉·冯，CFA (852) 3900 0826 wayne fung@cmbi.com.hk 2025年3月3日 中国民生银行国际 | 全球市场 | 股权研究 | 覆盖终止 联合能源（467 HK） 终止覆盖 鉴于资源分配更加合理，我们终止了对联合能源的覆盖。所有之前的推荐自覆 盖终止之日起不再有效。 请阅读最后一页的分析师认证和重要披露，更多来自彭博社的报告：响应CMBR或http://www.cm bi.com.hk 1 2025年3月3日 披露与免责声明 分析师认证 该研究报告内容（全部或部分）的主要研究员声明，关于本报告中所涵盖的证券或发行人：（1）所表达的所有观点准确反映了其个人对该证券或发行人的看法 ；并且（2）其薪酬的任何部分均未、现在或将来直接或间接与其在本报告中表达的特定观点相关。 此外，分析师确认，分析师及其关联人（根据香港证券及期货事务监察委员会发布的《行为守则》定义）在以下方面没有参与或交易本研究报告涵盖的股票： （1）在报告发布前30个日历日内未曾买卖本报告涵盖的股票；（2）在报告发布后3个营业日内不会买卖本报告涵盖的股票；（3）未担任本报告涵盖的任何香 港上市公司的董事 ...

Wayne FUNG, CFA (852) 3900 0826 waynefung@cmbi.com.hk PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE MORE REPORTS FROM BLOOMBERG: RESP CMBR OR http://www.cmbi.com.hk 1 3 Mar 2025 3 Mar 2025 CMB International Global Markets | Equity Research | Coverage Termination United Energy (467 HK) Termination of Coverage In view of better allocation of resources, we terminate coverage of United Energy. All previous recommendations are no longer valid, as of the date of termination of cove ...

证券研究报告 | 公司动态点评 2025 年 02 月 26 日 阿里巴巴-W（09988.HK） AI 战略持续推进，阿里云视觉生成基座模型万相 2.1 宣布开源 | 财务指标 | FY2023A | FY 2024A | FY 2025E | FY 2026E | FY 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 868,687 | 941,168 | 999,615 | 1,112,571 | 1,197,349 | | 增长率 yoy（%） | 1.83 | 8.34 | 6.21 | 11.30 | 7.62 | | 归母净利润（百万元） | 72,509 | 79,741 | 125,071 | 159,183 | 186,010 | | 增长率 yoy（%） | 17.03 | 9.97 | 56.32 | 27.27 | 16.85 | | ROE（%） | 7.35 | 8.11 | 12.54 | 14.81 | 15.59 | | EPS 最新摊薄（元） | 3.83 | 4.21 | 6.58 | 8.37 | ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of $55 for US shares and HK$43 for Hong Kong shares, indicating a potential upside of +60% and +62% respectively [6][13]. Core Insights - The company's 4Q24 revenue of $108.5 million represents a 65% year-over-year increase and is in line with market expectations. The operating loss was slightly better than expected, primarily impacted by a foreign exchange loss of $23.42 million [2][3]. - For 2025, the company projects total product revenue between $560 million and $590 million, reflecting a year-over-year growth of 40.4% to 45.4%, driven by strong growth in its core product, Eiger, and stable growth in existing products [3][4]. - The report highlights the strong growth of Eiger, which achieved sales of $30 million in 4Q24, a 492% increase year-over-year, and is expected to reach approximately $150 million in sales for 2025 [4][5]. Summary by Sections Financial Performance - In 4Q24, the company reported a net loss of $81.68 million, a 14.4% decrease year-over-year, but a 96% increase quarter-over-quarter. The gross margin for products was 61.5%, stable year-over-year but down 2.6 percentage points quarter-over-quarter [2][3]. - The company’s R&D expenses decreased to $52.25 million, down 36.2% year-over-year and 20.8% quarter-over-quarter, indicating improved cost management [2]. Future Catalysts - The report suggests focusing on the upcoming data updates for DLL3 ADC and potential international expansion. Several drugs are expected to submit NDA in China, with key data updates anticipated in 2Q25 [5][13]. - The company plans to cover 85% of the market potential for Eiger by 2025, up from 65% in 2024, which is expected to further enhance sales growth [4][5]. Market Position - The total market capitalization of the company is approximately $3.716 billion, with a recent average trading volume of $22 million over the past three months [6]. - The stock has a 52-week price range of $13.4 to $36.6, indicating significant volatility and potential for growth [6].

Investment Rating - The report initiates coverage with a "Buy" rating for Horizon Robotics [4][44]. Core Views - Horizon Robotics is positioned as a rare player in the domestic market, offering comprehensive intelligent driving solutions across all levels and scenarios, with significant growth potential anticipated [1][4]. - The company is expected to achieve revenues of 22.61 billion, 33.99 billion, and 57.32 billion yuan from 2024 to 2026, with net profits projected at -67.9 billion, -62.7 billion, and -44.6 billion yuan respectively [4][42]. Summary by Sections Company Overview - Horizon Robotics was established in 2015 and launched its first generation of automotive processing hardware, "Journey," in 2017. By 2020, it began equipping mass-produced vehicles from manufacturers like Changan and Li Auto. The new "Journey 6" series and Horizon SuperDrive solutions are set to be released in 2024, with cumulative shipments of the Journey series expected to reach 7 million by the end of 2024 [1][11]. Market Dynamics - The penetration rate of ADAS+AD solutions in China reached 57.1% in 2023, with projections indicating it could exceed 80% by 2027, driven by a compound annual growth rate of 48% [9][25]. - The report highlights the significance of the NOA function as a turning point for mid-to-high-level intelligent driving, with expectations for its configuration to become more accessible across various vehicle price segments [25][30]. Competitive Landscape - Horizon Robotics holds a leading position in the ADAS market, with a market share of 35.9% as of the first half of 2024, indicating a growing dominance among domestic solution providers [33]. - The company boasts a full-stack technology capability, which is considered a competitive moat, allowing it to offer comprehensive solutions from hardware to software [38]. Financial Performance - In the first half of 2024, Horizon Robotics reported revenues of 9.35 billion yuan, a year-on-year increase of 151.6%, with a gross margin of 79.0% [18][20]. - The automotive solutions segment generated 9.13 billion yuan in revenue during the same period, reflecting a 164.66% increase year-on-year, while the non-automotive solutions segment saw a decline [18][20]. Future Outlook - The company is expected to see substantial revenue growth in its automotive solutions segment, particularly with the anticipated mass production of the J6 series chips starting in 2025 [42][44]. - Revenue projections for 2024-2026 indicate significant growth, with automotive solutions expected to contribute the majority of income [42][44].

Investment Rating - The report maintains a "Buy" rating for the company and raises the target price to USD 324 for US stocks, HKD 194 for Hong Kong stocks, and CNY 273 for A-shares [1][11]. Core Insights - The company's revenue guidance for 2025 is stronger than market expectations, reaffirming the GAAP operating profit guidance [1][3]. - The company achieved a product revenue of USD 1.118 billion in Q4 2024, representing a year-over-year increase of 77.3% and a quarter-over-quarter increase of 12.5% [2]. - The adjusted non-GAAP operating profit for Q4 2024 was USD 78.6 million, marking the third consecutive quarter of profitability [2]. - The strong overseas sales of the drug Zebutinib contributed to a gross margin of 85.6% in Q4 2024, an increase of 2.4 percentage points year-over-year [2]. Revenue Guidance - The total product revenue guidance for 2025 is set at USD 4.9-5.3 billion, reflecting a year-over-year growth of 29.6% to 40.2%, which exceeds both Visible Alpha's expectation of 27% and the previous forecast of 21% [3]. - GAAP operating expenses are projected to be USD 4.1-4.4 billion, aligning with market expectations [3]. Product Performance - Zebutinib's global sales reached USD 828 million in Q4 2024, showing a year-over-year growth of 100.5% and a quarter-over-quarter growth of 20% [4]. - The US sales of Zebutinib amounted to USD 616 million, a 96.7% increase year-over-year, while European sales reached USD 113 million, up 147.8% year-over-year [4]. Research and Development Progress - The company is expected to have multiple research catalysts in 2025, including the announcement of global phase II data for Sonrotoclax in the second half of 2025 [5][10]. - The company plans to initiate several phase III clinical trials in 2025 for various indications [10]. Financial Projections - Revenue projections for 2025 are estimated at USD 4.972 billion, with a year-over-year growth of 30.5% [12][16]. - The company is expected to achieve a net profit of USD 81 million in 2025, transitioning from a loss in previous years [12][16].

事件 2025 年 2 月 28 日，公司披露其 MSCI ESG 评级由"BBB"上调至 "A"级，连续两年获得评级提升。 点评分析 ESG 为 A 的公司 ROE 更高，波动更小，吸引更多投资者。根据每日 经济新闻，实证研究 ESG 评级为 A 的上市公司其 ROE 算术平均值 明显高于其他公司。同时 ESG 评级为 A 的上市公司年化波动率最 低，其 60 个月年化波动率为 45.62%。我们认为 ESG 表现优越的公 司品牌强、治理好、声誉佳、风险低，具备长期竞争力，能够吸引 更多长线投资者及 ESG 投资者。 楼市春意渐浓，行业β修复中，贝壳率先受益。从前端看，根据贝 壳找房，春节后核心一二线城市的带看人数持续上升，在自然情况 下趋近甚至明显超越去年 9 月末新政后的水平。从备案看，最新 一周（2.22-2.28）47 城商品房销售 419 万方，环比+28.7%，同比 +28.6%；22 城二手房成交 282 万方，环比+14.2%，同比+64.4%。 今年小阳春正逐步兑现，随着行业β逐步修复，贝壳作为行业龙头 则率先受益。 贝壳入通在即，估值有望修复。3 月 10 日港股通名单进行调整， 在考察 ...